New drug to reduce protein in urine for diabetic kidney disease
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called LC-Z300-01 to see if it can reduce protein in the urine of people with type 2 diabetes and diabetic kidney disease. If you have diabetic kidney disease and are already on standard kidney-protective medications, this trial may offer a potential new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have type 2 diabetes and diabetic kidney disease (confirmed by a kidney biopsy or lab tests).
- Your blood sugar control (A1c) is 9% or less at the start of the study.
- You have protein in your urine—either a certain amount in two tests within 3 months or a 24-hour urine collection shows more than 300 mg of protein.
- Your kidney function (eGFR) is at least 60 mL/min.
- You are already on a stable dose of blood pressure/kidney medications (ACE inhibitor or ARB) for at least 4 weeks, or you can't take them due to side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug, R3R01, can help reduce protein leaking into the urine in people with diabetic kidney disease. It may offer a new option for managing kidney health.
This study tests a new medicine called AP303 for people with type 2 diabetes and chronic kidney disease. The goal is to see if it is safe and how the body processes it. If you have diabetes and your kidneys are not working as well as they used to, this trial might help find new treatment options.
This Phase 2 study tests whether adding NAD can improve kidney health in people with diabetes-related kidney disease. It is designed for people with certain urine lab results showing kidney stress, while keeping blood sugar and safety limits within range.
This study tests a four-drug combination to see if it can better protect the kidneys in people with type 2 diabetes and kidney disease. If you qualify, you may receive this combination therapy and be monitored for 6 months.
This trial tests if dapagliflozin, a medication that lowers blood sugar and protects the kidneys, can reduce protein in the urine of children with inherited kidney disease. It may help preserve kidney function when added to standard blood pressure medication.
This trial tests a new medicine, YG1699, in people with diabetic kidney disease, including those on dialysis. It aims to see how the drug works in your body and how it affects your blood sugar.
Hear when a new Diabetic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.